What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases
- PMID: 18187210
- DOI: 10.1016/j.tips.2007.11.006
What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases
Abstract
Leukotrienes have physiological roles in innate immune responses and pathological roles in inflammatory diseases, such as asthma, allergic rhinitis and atherosclerosis. Anti-leukotriene therapy has proven benefits in the treatment of respiratory disease, either through the inhibition of leukotriene synthesis or the selective antagonism of leukotriene receptors. The first committed step in the synthesis of leukotrienes is the oxidation of arachidonic acid (AA) by 5-lipoxygenase (5-LO), and the integral membrane protein 5-lipoxygenase-activating protein (FLAP) is an essential partner of 5-LO for this process. FLAP was molecularly identified via a photoaffinity probe and an affinity gel based on MK-886, a selective leukotriene inhibitor that has no activity against broken-cell preparations of 5-LO. Several FLAP inhibitors showed efficacy in early clinical trials in asthma but were not developed commercially for unpublished reasons. Recently, the FLAP (ALOX5AP) gene has been linked to risk for myocardial infarction, stroke and restenosis, reigniting pharmaceutical interest in this target. In addition, the recent determination of the crystal structure of inhibitor-bound FLAP offers exciting potential for novel FLAP inhibitor design.
Similar articles
-
FLAP inhibitors for the treatment of inflammatory diseases.Curr Opin Investig Drugs. 2009 Nov;10(11):1163-72. Curr Opin Investig Drugs. 2009. PMID: 19876784 Review.
-
Amino acid residues of 5-lipoxygenase-activating protein critical for the binding of leukotriene biosynthesis inhibitors.J Lipid Mediat. 1993 Mar-Apr;6(1-3):31-42. J Lipid Mediat. 1993. PMID: 8357989
-
Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein.Science. 2007 Jul 27;317(5837):510-2. doi: 10.1126/science.1144346. Epub 2007 Jun 28. Science. 2007. PMID: 17600184
-
Heart disease. Gene suggests asthma drugs may ease cardiovascular inflammation.Science. 2004 Feb 13;303(5660):941. doi: 10.1126/science.303.5660.941a. Science. 2004. PMID: 14963296 No abstract available.
-
Drug discovery approaches targeting 5-lipoxygenase-activating protein (FLAP) for inhibition of cellular leukotriene biosynthesis.Eur J Med Chem. 2018 Jun 10;153:34-48. doi: 10.1016/j.ejmech.2017.07.019. Epub 2017 Jul 13. Eur J Med Chem. 2018. PMID: 28784429 Review.
Cited by
-
Arachidonic acid promotes the binding of 5-lipoxygenase on nanodiscs containing 5-lipoxygenase activating protein in the absence of calcium-ions.PLoS One. 2020 Jul 9;15(7):e0228607. doi: 10.1371/journal.pone.0228607. eCollection 2020. PLoS One. 2020. PMID: 32645009 Free PMC article.
-
MK591, a second generation leukotriene biosynthesis inhibitor, prevents invasion and induces apoptosis in the bone-invading C4-2B human prostate cancer cells: implications for the treatment of castration-resistant, bone-metastatic prostate cancer.PLoS One. 2015 Apr 15;10(4):e0122805. doi: 10.1371/journal.pone.0122805. eCollection 2015. PLoS One. 2015. PMID: 25875826 Free PMC article.
-
Lysophospholipid acyltransferases and leukotriene biosynthesis: intersection of the Lands cycle and the arachidonate PI cycle.J Lipid Res. 2019 Feb;60(2):219-226. doi: 10.1194/jlr.S091371. Epub 2019 Jan 3. J Lipid Res. 2019. PMID: 30606731 Free PMC article. Review.
-
5-Lipoxygenase DNA methylation and mRNA content in the brain and heart of young and old mice.Neural Plast. 2009;2009:209596. doi: 10.1155/2009/209596. Epub 2009 Dec 13. Neural Plast. 2009. PMID: 20052386 Free PMC article.
-
Role of leukotrienes in exercise-induced bronchoconstriction.Curr Allergy Asthma Rep. 2009 Jan;9(1):18-25. doi: 10.1007/s11882-009-0003-8. Curr Allergy Asthma Rep. 2009. PMID: 19063820
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
